Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 348 shares, a decrease of 76.4% from the July 15th total of 1,472 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,908 shares, the short-interest ratio is presently 0.2 days.

Daxor Stock Up 2.5%

NASDAQ:DXR traded up $0.25 during mid-day trading on Thursday, reaching $10.45. The company’s stock had a trading volume of 527 shares, compared to its average volume of 7,061. The company’s fifty day simple moving average is $10.36 and its two-hundred day simple moving average is $10.76. Daxor has a twelve month low of $8.56 and a twelve month high of $14.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of Daxor in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.

Institutional Trading of Daxor

Institutional investors have recently made changes to their positions in the stock. Aristides Capital LLC purchased a new stake in shares of Daxor during the 1st quarter valued at about $403,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new position in Daxor during the 1st quarter worth $245,000. Osaic Holdings Inc. acquired a new position in Daxor during the 2nd quarter worth $86,000. Crescent Grove Advisors LLC bought a new stake in shares of Daxor in the 1st quarter worth about $104,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Daxor in the 4th quarter valued at about $184,000. 1.34% of the stock is owned by hedge funds and other institutional investors.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.